-
公开(公告)号：US10463674B2
公开(公告)日：2019-11-05
申请号：US15034306
申请日：2014-11-05
Applicant: Sentiss Pharma Private Limited
Inventor： Mandar V. Shah , Deepak Bahri , Divya Pandit
Abstract: The present invention provides a process of manufacturing a sterile, ophthalmic pharmaceutical suspension comprising sterile active ingredient(s) such as sterile carbonic anhydrase inhibitors (CAIs) wherein the process does not involve the use of any special equipment's such as ball mill, milling bottle and/or jet mill The present process is simple, cost effective and efficient.
-
公开(公告)号：US09801813B2
公开(公告)日：2017-10-31
申请号：US15028930
申请日：2014-10-13
Applicant: Sentiss Pharma Private Limited
Inventor： Mandar V. Shah , Deepak Bahri , Manish Kumar Singh
IPC: A61K31/382 , A61K31/535 , A61K31/5377 , A61K9/00 , A61K9/08 , A61K47/38 , A61K47/02 , A61K47/12 , A61K47/26 , A61K45/06
CPC classification number: A61K9/0048 , A61K9/08 , A61K31/382 , A61K31/535 , A61K31/5377 , A61K45/06 , A61K47/02 , A61K47/12 , A61K47/26 , A61K47/38 , A61K2300/00
Abstract: The present invention relates to a process for manufacturing an ophthalmic formulation of a carbonic anhydrase inhibitor, hydroxyl ethyl cellulose (HEC), and a beta-adrenergic antagonist for use in the treatment of ocular hypertension and glaucoma wherein the ophthalmic pharmaceutical formulation is devoid of benzalkonium chloride or any other preservatives. The present process for manufacturing is simpler, cost effective process to prepare the pharmaceutical ophthalmic formulation in a single tank, without the use of additional tanks that can be sterile filtered.
-
公开(公告)号：US11285163B2
公开(公告)日：2022-03-29
申请号：US15520217
申请日：2015-10-16
Applicant: SENTISS PHARMA PRIVATE LIMITED
Inventor： Mandar V. Shah , Deepak Bahri
IPC: A61K31/5575 , A61K47/26 , A61K45/06 , A61K9/00 , A61K47/34 , A61K31/5377 , A61K31/542
Abstract: Disclosed herein an ophthalmic formulation comprises carbonic anhydrase inhibitor(s) alone, in an aqueous solution or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents and a manufacturing process thereof.
The present invention further relates to the composition(s) manufactured by the process described herein and methods for treating persons suffering from glaucoma or ocular hypertension.
In particular, the persons are treated with carbonic anhydrase inhibitor(s) alone or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents to control their intraocular pressure (IOP).
Further disclosed herein the formulations as manufactured relate to a highly solubilized form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.-
公开(公告)号：US20140151322A1
公开(公告)日：2014-06-05
申请号：US14111259
申请日：2012-04-12
Applicant: Deepak Bahri , Dilip Chaturvedi , Anupam Chanda
Inventor： Deepak Bahri , Dilip Chaturvedi , Anupam Chanda
IPC: B65D1/02
CPC classification number: B65D1/0246 , A61F9/0008 , B65D47/123 , B65D47/18
Abstract: Disclosed is a two piece closure caps for bottle containers having a threaded neck portion onto which the cap is intended to fit. More specifically, the bottle container is used for storing and dispensing pharmaceutical/medical product. The medical product is in the liquid form for ophthalmic and/or Ear related infections/disease.
Abstract translation: 公开了一种用于瓶容器的两件式封盖，其具有螺纹颈部，盖将用于装配。 更具体地，瓶容器用于存储和分配药物/医疗产品。 医疗产品是用于眼科和/或耳朵相关感染/疾病的液体形式。
-
公开(公告)号：US20230218611A1
公开(公告)日：2023-07-13
申请号：US17997203
申请日：2021-04-28
Applicant: SENTISS PHARMA PRIVATE LIMITED
Inventor： Manoj NAHAR , Shailendra PRASAD , Mallinath HARWALKAR , Kishor DEO , Deepak BAHRI
IPC: A61K31/498 , A61K31/542 , A61K47/36 , A61K47/10 , A61K9/00 , A61P27/06
CPC classification number: A61K31/498 , A61K31/542 , A61K47/36 , A61K47/10 , A61K9/0048 , A61P27/06
Abstract: An aqueous ophthalmic composition, comprising: a therapeutically effective amount of brimonidine or their salts thereof; a therapeutically effective amount of brinzolamide or their salts thereof; buffers at a concentration that is at least about 0.05% w/v to 5.0% w/v of the ophthalmic composition; a preservative and; pharmaceutically acceptable excipients, wherein the pH of said composition is less than 8.0.
-
Patent Agency Ranking
公开(公告)号：US20160331745A1
公开(公告)日：2016-11-17
申请号：US15107576
申请日：2014-12-18
Applicant: SENTISS PHARMA PRIVATE LIMITED
Inventor： Mandar V. Shah , Deepak Bahri
IPC: A61K31/498 , A61K47/18 , A61K47/02 , A61K9/00 , A61K47/38
CPC classification number: A61K31/498 , A61K9/0048 , A61K47/02 , A61K47/186 , A61K47/38
Abstract: The present invention provides an aqueous ophthalmic composition comprising an alpha-2 adrenergic receptor agonist and a non-ionic cellulosic polymer, the solution having a pH less than 6.5. The present invention also provides an aqueous ophthalmic composition comprising an alpha-2 adrenergic receptor agonist and a benzododecinium halide. Also provided are methods of manufacture, use and method of reducing intraocular pressure in the patient in need thereof.
Abstract translation: 本发明提供包含α-2肾上腺素能受体激动剂和非离子纤维素聚合物的水性眼用组合物，该溶液的pH值小于6.5。 本发明还提供了一种含有α-2肾上腺素能受体激动剂和卤代苯并十一烷的眼用组合物。 还提供了在有需要的患者中降低眼内压的制造方法，使用方法和方法。
-
公开(公告)号：US20240065977A1
公开(公告)日：2024-02-29
申请号：US18270389
申请日：2021-12-29
Applicant: SENTISS PHARMA PRIVATE LIMITED
Inventor： Rajesh RAO , Vasundera SINGH, SR. , Tarun Kumar MANDAL , Deepak BAHRI
CPC classification number: A61K9/08 , A61K31/137 , A61K31/46 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/186 , A61K47/36
Abstract: The present invention provides an ophthalmic composition comprising a combination of mydriatic agent and anti-muscarinic agent along with pharmaceutically acceptable excipients, wherein the pH of the composition is in the range of 3.5 to 8.5. The ophthalmic composition of the present invention has synergistic mydriasis effect to induce pupil dilation (Mydriasis) in ophthalmic surgery for pre-operative preparation.
-
公开(公告)号：US11826429B2
公开(公告)日：2023-11-28
申请号：US16811674
申请日：2020-03-06
Applicant: SENTISS PHARMA PRIVATE LIMITED
Inventor： Mandar V. Shah , Deepak Bahri
CPC classification number: A61K47/34 , A61K9/0048 , A61K9/08 , A61K31/542 , A61K47/26 , A61K47/32
Abstract: A sterile aqueous formulation of a carbonic anhydrase inhibitor such as brinzolamide in combination with polymers like Soluplus® and a surfactant like polysorbate 80, as well as methods of preparation thereof, is disclosed. The formulation relates to the highly solubilized or an amorphous form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.
-
9.发明公开公开(公告)号：US20230233572A1
公开(公告)日：2023-07-27
申请号：US18009347
申请日：2021-05-14
Applicant: SENTISS PHARMA PRIVATE LIMITED
Inventor： KOSHY PRAVEEN VARGHESE , SUDHEER DASARIPALLI , GUNEET SINGH RANDHAWA , TARUN KUMAR MANDAL , MALLINATH HARWALKAR , KISHOR DEO , DEEPAK BAHRI
IPC: A61K31/5383 , A61K31/407 , A61K9/00 , A61P31/04 , A61P27/02 , A61K47/18 , A61K47/32 , A61K47/40
CPC classification number: A61K31/5383 , A61K31/407 , A61K9/0048 , A61P31/04 , A61P27/02 , A61K47/186 , A61K47/183 , A61K47/32 , A61K47/40
Abstract: The present invention relates to an ophthalmic pharmaceutical composition comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent along with a complexing agent and water. The composition is having a pH between 4 and 8. The present invention also relates to the methods of making an ophthalmic pharmaceutical composition and there uses thereof. The present invention also provides a method of treating and/or preventing an ophthalmic condition in a patient.
-
公开(公告)号：US20230143595A1
公开(公告)日：2023-05-11
申请号：US17995071
申请日：2021-03-30
Applicant: SENTISS PHARMA PRIVATE LIMITED
Inventor： Manish Kumar SINGH , Sai Kiran JANA , Mallinath HARWALKAR , Kishor DEO , Deepak BAHRI
CPC classification number: A61L2/0017 , A61K9/0048 , A61K47/26 , A61K47/36 , A61K31/5377 , A61K47/18 , A61K9/0024
Abstract: The present invention provides the sterilization of an ophthalmic composition comprising timolol or salt thereof optionally with pharmaceutically acceptable agent(s) wherein the sterilization is achieved through aseptic filtration technique. Further the present invention provides the sterilization process by optimising the process parameters by varying the heating time at a temperature to control the viscosity of the ophthalmic composition of present invention through aseptic filtration technique wherein the filtration is done under aseptic condition through 0.45 μm clarification pre-filter followed by 0.2μ sterilizing grade filter. The process is simple and economical.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.014 seconds)
